Zealand Pharma expands management team

Danish biopharmaceutical firm makes three senior appointments

Danish biopharmaceutical company Zealand Pharma has appointed Christian Grondahl as chief scientific officer, Mats Blom as chief financial officer and John Hyttel as senior vice president for operations.

"Together they bring a wealth of experience, energy and skills to Zealand Pharma as we continue to advance our growth strategy," said David Horn Solomon, chief executive of Zealand Pharma.

Grondahl starts on 1 April, joining the firm from Novo Nordisk, where until recently he was corporate vice president for strategic alliances.

Blom, who joined the company earlier this month, was cfo of Swedish Orphan International, which recently merged with Biovitrum to form Swedish Orphan-Biovitrum of Stockholm.

Hyttel, who became senior vice president for operations on 1 March, founded Zealand Pharma in 1998. He worked for H Lundbeck for 30 years prior to joining Zealand.

Zealand's most advanced project, Lixisenatide (ZP10/AVE0010), a GLP-1 agonist for the treatment of Type II diabetes has been out licensed to Sanofi-Aventis of France. Sanofi-Aventis is completing 9 Phase III trials with first results to be released in June. Sanofi-Aventis is also commercialising a Lantus-Lixisenatide combination product for the treatment of Type II diabetes that has completed Phase I clinical studies. Submission of IND/MAA for Lixisenatide is expected in 2011.

You may also like

Research & Development

Quotient Sciences extends partnership for ultra-rare disease treatment

This collaboration reinforces Quotient Sciences’ commitment to supporting the manufacture of niche and smaller volume commercial products often overlooked by larger CDMOs
Research & Development

OSE Immunotherapeutics receives positive IDMC review for Phase III ARTEMIA trial

OSE Immunotherapeutics SA has received a second positive recommendation from the Independent Data Monitoring Committee to continue its Phase III ARTEMIA trial of Tedopi in advanced non-small cell lung cancer
Research & Development

Vilnius University scientists reveal new role for CRISPR-Cas9 in bacterial immunity

The researchers report in Molecular Cell that the CRISPR-Cas9 protein plays a previously unknown role in selecting and integrating viral DNA fragments during bacterial immune memory formation
Research & Development

Lilly’s Orforglipron beats oral semaglutide in Phase III ACHIEVE-3 trial with superior weight loss

Head-to-head data published in The Lancet show Eli Lilly's oral GLP-1 candidate orforglipron delivered significantly greater HbA1c reductions and weight loss than oral semaglutide in adults with type 2 diabetes, supporting global regulatory submissions
Regulatory

Johnson & Johnson files FDA application for IMAAVY in wAIHA

Johnson & Johnson has submitted an sBLA to the US Food and Drug Administration seeking approval of IMAAVY as the first-ever treatment for warm autoimmune haemolytic anaemia, supported by Phase II/III ENERGY trial data showing rapid and durable haemoglobin response
Research & Development

Almirall advances etherna’s mRNA/LNP therapy LAD116 into IND-enabling studies

Almirall has selected LAD116, developed using etherna's intratumoral mRNA/LNP platform, for IND-enabling studies in non-melanoma skin cancer, marking a key milestone toward GMP manufacturing and Phase I clinical trials
Research & Development

SPARK THE MIDLANDS backs Aston University anti-cancer bone paste collaboration

A collaboration between Aston University and Royal Orthopaedic Hospital NHS Foundation Trust has secured support from SPARK THE MIDLANDS to advance a minimally invasive gallium-doped injectable paste for treating primary and metastatic bone cancer
Subscribe now